Zacks Investment Research cut shares of Assembly Biosciences (NASDAQ:ASMB) from a buy rating to a hold rating in a research note published on Wednesday, March 14th.
According to Zacks, “Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly’s product portfolio consists of two late stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for the treatment of fecal incontinence. The Company is also developing novel microbiome-based technology for targeted oral delivery of therapeutic bacteria, complex proteins, viral antigens and small molecules to treat intractable infectious diseases of the GI tract, such as C. difficile infections. Assembly Biosciences Inc., formerly known as Ventrus Biosciences, Inc., is based in New York. “
Several other equities analysts also recently weighed in on ASMB. BidaskClub cut Assembly Biosciences from a strong-buy rating to a buy rating in a report on Wednesday, December 6th. ValuEngine cut Assembly Biosciences from a hold rating to a sell rating in a report on Thursday, December 7th. B. Riley began coverage on Assembly Biosciences in a report on Friday, January 5th. They set a neutral rating and a $35.00 price objective on the stock. Finally, Jefferies Group raised their price objective on Assembly Biosciences to $75.00 and gave the stock a buy rating in a report on Thursday, March 8th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company. The stock presently has a consensus rating of Hold and a consensus price target of $54.25.
ASMB opened at $44.61 on Wednesday. The company has a market cap of $963.15, a price-to-earnings ratio of -17.36 and a beta of 0.74. Assembly Biosciences has a 52 week low of $18.60 and a 52 week high of $67.36.
In related news, Director William R. Ringo sold 1,000 shares of Assembly Biosciences stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $46.86, for a total value of $46,860.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last ninety days, insiders have sold 3,000 shares of company stock worth $152,550. Corporate insiders own 19.60% of the company’s stock.
A number of hedge funds have recently modified their holdings of the business. Jennison Associates LLC boosted its stake in Assembly Biosciences by 19.6% in the fourth quarter. Jennison Associates LLC now owns 2,120,300 shares of the biopharmaceutical company’s stock valued at $95,944,000 after acquiring an additional 347,025 shares during the period. BlackRock Inc. boosted its position in shares of Assembly Biosciences by 19.6% during the fourth quarter. BlackRock Inc. now owns 1,078,097 shares of the biopharmaceutical company’s stock worth $48,784,000 after buying an additional 176,976 shares during the period. Vanguard Group Inc. boosted its position in shares of Assembly Biosciences by 21.2% during the second quarter. Vanguard Group Inc. now owns 610,916 shares of the biopharmaceutical company’s stock worth $12,615,000 after buying an additional 107,065 shares during the period. Perceptive Advisors LLC boosted its position in shares of Assembly Biosciences by 21.5% during the fourth quarter. Perceptive Advisors LLC now owns 536,626 shares of the biopharmaceutical company’s stock worth $24,282,000 after buying an additional 94,793 shares during the period. Finally, Rock Springs Capital Management LP boosted its position in shares of Assembly Biosciences by 15.4% during the fourth quarter. Rock Springs Capital Management LP now owns 450,000 shares of the biopharmaceutical company’s stock worth $20,363,000 after buying an additional 60,000 shares during the period. Institutional investors own 76.81% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Zacks Investment Research Lowers Assembly Biosciences (NASDAQ:ASMB) to Hold” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another website, it was illegally stolen and republished in violation of U.S. and international copyright law. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/07/assembly-biosciences-asmb-downgraded-by-zacks-investment-research.html.
Assembly Biosciences Company Profile
Assembly Biosciences, Inc operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States.
Get a free copy of the Zacks research report on Assembly Biosciences (ASMB)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.